scholarly journals Randomized sham-controlled, double-blind, multicenter clinical trial on the effect of percutaneous radiofrequency at the ramus communicans for lumbar disc pain

2016 ◽  
Vol 21 (3) ◽  
pp. 520-529 ◽  
Author(s):  
C.W.J. van Tilburg ◽  
D.L. Stronks ◽  
J.G. Groeneweg ◽  
F.J.P.M. Huygen
Keyword(s):  
Clinical Trial ◽  
Lumbar Disc ◽  
Multicenter Clinical Trial ◽  
Double Blind ◽  
Ramus Communicans

scholarly journals Rationale and Design of BeatNF2 Trial: A Clinical Trial to Assess the Efficacy and Safety of Bevacizumab in Patients with Neurofibromatosis Type 2 Related Vestibular Schwannoma

2021 ◽  
Vol 28 (1) ◽  
pp. 726-739
Author(s):  
Masazumi Fujii ◽  
Masao Kobayakawa ◽  
Kiyoshi Saito ◽  
Akihiro Inano ◽  
Akio Morita ◽  
...  
Keyword(s):  
Clinical Trial ◽  
Neurofibromatosis Type ◽  
Primary Objective ◽  
Neurofibromatosis Type 2 ◽  
Efficacy And Safety ◽  
Multicenter Clinical Trial ◽  
Double Blind ◽  
Hearing Function ◽  
Initial Intervention

Neurofibromatosis type 2 (NF2) causes bilateral vestibular schwannomas (VSs), leading to deafness. VS is treated by surgery or radiation, but neither treatments prevent hearing loss. Bevacizumab was found to be effective in suppressing the tumor’s growth and may help to improve hearing. We are conducting a randomized, double-blind, multicenter clinical trial to verify the efficacy and safety of bevacizumab in NF2-related VS. The primary objective is to evaluate the efficacy of bevacizumab in improving hearing in the affected ear. One of the secondary objectives is to evaluate bevacizumab’s efficacy in rechallenge treatment in relapsed cases. Sixty patients will randomly receive either bevacizumab or a placebo and will be clinically observed for 48 weeks in the initial intervention phase. In the first half (24 weeks), they will receive either 5 mg/kg of bevacizumab or a placebo drug. In the second half, all patients will receive 5 mg/kg of bevacizumab. If hearing function deteriorated in a patient who had shown improvement during the first phase, a rechallenge dose with bevacizumab would be offered.

S-Adenosylmethionine in alcoholic liver cirrhosis: a randomized, placebo-controlled, double-blind, multicenter clinical trial

1999 ◽  
Vol 30 (6) ◽  
pp. 1081-1089 ◽  
Author(s):  
Jose M Mato ◽  
Javier Cámara ◽  
Javier Fernández de Paz ◽  
Llorenç Caballería ◽  
Susana Coll ◽  
...  
Keyword(s):  
Clinical Trial ◽  
Liver Cirrhosis ◽  
Alcoholic Liver Cirrhosis ◽  
Multicenter Clinical Trial ◽  
Double Blind

A randomized, double-blind, multicenter clinical trial on the efficacy of ivermectin against intestinal nematode infections in China

Acta Tropica ◽  
2008 ◽  
Vol 106 (3) ◽  
pp. 190-194 ◽  
Author(s):  
Li-Yong Wen ◽  
Xiao-Lan Yan ◽  
Feng-Hua Sun ◽  
Yue-Yi Fang ◽  
Ming-Jin Yang ◽  
...  
Keyword(s):  
Clinical Trial ◽  
Multicenter Clinical Trial ◽  
Double Blind ◽  
Intestinal Nematode
Sign in / Sign up

Export Citation Format

Share Document